Oncovita, a spin-off from the Institut Pasteur, has won the call for projects "Innovation in biotherapies and bioproduction" as part of the France 2030 investment plan. The company will receive €4.5 million in funding from Bpifrance to support the development of its immunotherapeutic cancer vaccine, MVdeltaC.
The company will also benefit from €3.5 million in private funding. This total of 8 million euros will be used to accelerate preclinical and clinical development of the MVdeltaC vaccine.
Oncovita has used the measles vaccine virus to develop this vaccine candidate: the MeasoviR technology platform enables the genome of the vaccine virus to be modified in order to enhance its anti-tumor properties. MVdeltaC's immuno-oncolytic efficacy has been demonstrated in both in-vitro and in-vivo tumor models. Preclinical pharmacological and regulatory safety trials are currently being finalized. The next step is a first basket trial in 5 solid tumor types, as well as the identification of relevant markers of tumor sensitivity to the MVdeltaC vaccine.
Oncovita also plans to develop an industrial production process.
